Key End Points in Clinical Trials

Author(s):

Zahra Mahmoudjafari, PharmD, MBA, BCOP, FHOPA,Amir Ali, PharmD, BCOP

Key Takeaways

Progression-free survival and overall survival are key endpoints in multiple myeloma trials, crucial for evaluating treatment efficacy.
Stringent eligibility criteria in clinical trials may limit their applicability to real-world scenarios, necessitating more inclusive designs.
Incorporating diverse patient populations, including those with comorbidities, can enhance the relevance of trial outcomes.
Real-world endpoints such as quality of life and treatment tolerability should be considered for a comprehensive understanding of therapeutic impact.

Panelists discuss how clinical trials in multiple myeloma can be improved to better reflect real-world scenarios and patient outcomes, emphasizing the importance of end points such as progression-free survival, overall survival, and quality of life measures, while also considering ways to increase trial inclusivity and applicability to diverse patient populations.

EP: 1.Treatment Landscape for Transplant-Eligible Patients with NDMM

EP: 2.Frontline Treatment and Sequencing Therapy

EP: 3.Impact of Transplant Eligibility on Treatment Selection

EP: 4.Treatment Regimen Considerations

EP: 5.Impact of IFM 2009 and DETERMINATION Studies

Now Viewing

EP: 6.Key End Points in Clinical Trials

EP: 7.Real-World Considerations for New Therapies

EP: 8.Challenges in Adopting Novel Therapies

EP: 9.Evaluating New Data for Transplant-Eligible Patients With NDMM: PERSEUS, IsKia, and GMMG HD7

EP: 10.Impact of SC Daratumumab

EP: 11.SC vs IV Administration Methods

EP: 12.Pharmacists’ Roles in MM Management

EP: 13.Pharmacists’ Roles on the Multidisciplinary Team

EP: 14.Personalizing Treatments and Patient Education

EP: 15.Addressing Payer Coverage Challenges

EP: 16.Unmet Needs for Transplant-Eligible NDMM

EP: 17.Final Thoughts

Video content above is prompted by the following:

As a provider, what primary end points in clinical trials are most clinically significant, and how can multiple myeloma clinical trials be changed to be more applicable to or inclusive of real-world scenarios?

Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.

Subscribe Now!